Quellos High Throughput Screening Core
Grandori Bio
Carla Grandori, M.D. Ph.D.
Research Associate Professor, University of Washington
Director, Quellos High Throughput Screening Core and Affiliate Investigator, Fred Hutchinson
Formerly Research Fellow at Rosetta, a wholly owned subsidiary of Merck
Dr. Carla Grandori is an experienced cancer molecular and cellular biologist that has been a pioneer in the application of genomic technologies and high throughput screening to unravel how oncogenes alter cell behavior. Trained as an M.D. she later decided to pursue a career in science to ultimately contribute to novel therapeutics and thus obtained her Ph.D. at the Rockefeller University in New York. She joined the Fred Hutchinson in 1991 where her work led to major advances toward understanding the transcriptional program triggered the Myc oncogene, which is critically involved in many human cancers. Following her post-doctoral training, Dr. Grandori maintained independent funding, including an R29, first independent award from the NCI, and recently an R01, from the National Institute of Aging. Dr. Grandori joined Rosetta, Merck, in 2006 to exploit her expertise toward identifying new therapeutic cancer targets. In addition, she had continued to manage her R01 by coordinating projects between Rosetta and the Fred Hutchinson, where she remains as an Affiliate Investigator. Her experience in High Throughput Screening and managerial skills acquired while at Merck will be essential to the development and maintenance of the HTS program.
Martins Bio
Timothy J Martins, Ph.D.
Co-Director, Quellos High Throughput Screening Core
Formerly, Director of Biomolecular Sciences and Technology
ICOS Corporation, a wholly owned subsidiary of Eli Lilly & Co.
Dr. Timothy J Martins was one of the original scientists at ICOS Corporation and remained there for its entire 17 years of operation. Prior to that he received his BS in Biochemistry at UC Riverside, Ph.D. in Pharmacology at Univ. Washington School of Medicine and performed his postdoctoral fellowship at Harvard University's Biological Laboratories. Dr. Martins' department performed all high throughput screening assays for ICOS and was the primary provider of target-based, primary cell-based and pharmaceutical profiling data to project leaders and medicinal chemists involved in chemical optimization programs at the company. Besides providing high throughput screening and chemical optimization program support, his department oversaw ICOS' chemical repository that included library acquisition, storage, inventory and distribution functions. Prior to becoming departmental head, Dr. Martins served as an Associate Director, Research and was instrumental in ICOS' Bench to "First-in-Man" approach to research and was directly involved in their PDE5 inhibitor (Cialis) and PDE4 inhibitor (clinical entry) discovery/optimization programs. Recently emerging from an early retirement, he is currently overseeing implementation of small molecule screening at the Core facility and general management of the screening laboratory.
Annis Bio
James Annis, B.A., AAS
Research Scientist, Quellos High Throughput Screening Core
Mr. James Annis entered the biotech community in 1996 at Icogen Inc. where he worked with a team to pilot and characterize protein therapeutics for the treatment of disabling haplo-insufficiencies. This work has lead to IND's, clinical trials, worldwide patents, and market ready therapeutics. Joining Rosetta / Merck & Co., Inc. in 2004 he became involved in the development and industrialization of Lentiviral mediated shRNA HTS screening capabilities within the Molecular Profiling franchise. Additionally Mr. Annis has developed several HTS siRNA assays across multiple disease areas that were utilized for biological network validation, compound enhancement/suppression and target discovery. Mr. Annis holds a BA in Natural Sciences/Mathematics from Thomas Edison State College and an AAS in Biotechnology from SCCC.
